Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Penumbra, Inc. (NYSE: PEN) had its price target raised by analysts at Piper Sandler from $235.00 to $250.00. They now have an "overweight" rating on the stock.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Here's Why Penumbra (PEN) is a Strong Momentum Stock [Yahoo! Finance]
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options